| abstract |
Compounds having the following formula (I). where Ri is e.g. H, C 1-4 alkyl, C 1-4 alkenyl, C 1-4 aryl, C 1-4 heteroaromatic ring or C 1-4 non-aromatic ring; Rog Rer e.g. in each case independently H, C1-alkyl, C1-alkenyl, C1-aryl, C1-heteroaromatic ring or C1-non-aromatic ring; or an amino acid radical or a. dipeptide or tripeptide chain or an imitation thereof, wherein the amino acid radicals are selected from the group consisting of Glu, Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp, Ser, Thr, Cys, Met, Asn and Gln, and which in each case optionally terminated with -R .; In each case, H, C 1-4 alkyl, C 1-4 alkenyl, C 1-4 alkyl-C 1-4 aryl, C 0-20 alkyl-C 1-4 heteroaromatic ring, C 1-4 non-aromatic ring optionally containing 1-3. heteroatoms selected from the group consisting of 0, N and S; and R 7 is in each case C 1-4 alkyl, C 1-4 alkenyl, C 1-10 aryl, C 1-4 heteroaromatic ring, C 1-4 non-aromatic ring optionally containing 1-3 heteroatoms selected from the group consisting of 0, N and S, -C (O) R, -C (O) OR; and X and Y are independently Br, Cl, I, F, OH, OR or NRR, and at least one of X and Y is NRR; or a pharmaceutically acceptable salt thereof, may be used in the treatment of a patient having cancer. |